These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 8305785)
21. Candesartan cilexetil: an angiotensin II receptor blocker. Stoukides CA; McVoy HJ; Kaul AF Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830 [TBL] [Abstract][Full Text] [Related]
22. Peptides as targets for antihypertensive drug development. Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647 [TBL] [Abstract][Full Text] [Related]
23. Angiotensin receptor antagonists. Wong W; Howes L Aust Fam Physician; 2000 Jul; 29(7):653-5, 658. PubMed ID: 10914449 [TBL] [Abstract][Full Text] [Related]
24. Losartan: first of a new class of angiotensin antagonists for the management of hypertension. Carr AA; Prisant LM J Clin Pharmacol; 1996 Jan; 36(1):3-12. PubMed ID: 8932538 [TBL] [Abstract][Full Text] [Related]
25. Antihypertensive therapy targeted to the needs of the patient: focus on the renin-angiotensin system; older and newer agents. Itskovitz HD Clin Cardiol; 1995 Jun; 18(6 Suppl 3):III 23-8. PubMed ID: 7634560 [TBL] [Abstract][Full Text] [Related]
26. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154 [TBL] [Abstract][Full Text] [Related]
27. [Angiotensin-II receptor blockers]. Metelitsa VI Ter Arkh; 1996; 68(8):64-7. PubMed ID: 9019837 [No Abstract] [Full Text] [Related]
28. Rationale for the chemical development of angiotensin II receptor antagonists. Wexler RR; Carini DJ; Duncia JV; Johnson AL; Wells GJ; Chiu AT; Wong PC; Timmermans PB Am J Hypertens; 1992 Dec; 5(12 Pt 2):209S-220S. PubMed ID: 1290616 [TBL] [Abstract][Full Text] [Related]
29. [Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers]. Pichler M; Klein W; Huber K; Pachinger O Wien Med Wochenschr; 1996; 146(11):228-31. PubMed ID: 8928520 [TBL] [Abstract][Full Text] [Related]
30. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
31. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Burrell LM; Johnston CI Drugs Aging; 1997 Jun; 10(6):421-34. PubMed ID: 9205848 [TBL] [Abstract][Full Text] [Related]
32. [Non-peptide antagonists to angiotensin II receptors. A review]. Schambye HT; Hjorth SA; Schwartz TW Ugeskr Laeger; 1993 Nov; 155(44):3558-62. PubMed ID: 8236577 [TBL] [Abstract][Full Text] [Related]
33. Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Awan NA; Mason DT Am Heart J; 1996 Jan; 131(1):177-85. PubMed ID: 8554006 [TBL] [Abstract][Full Text] [Related]
34. The preclinical basis of the therapeutic evaluation of losartan. Timmermans PB; Wong PC; Chiu AT; Smith RD J Hypertens Suppl; 1995 Jul; 13(1):S1-13. PubMed ID: 18800450 [TBL] [Abstract][Full Text] [Related]